- Home
- ANL vs ALDX Comparison
ANL vs ALDX Comparison
Compare ANL & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANL | ALDX |
|---|---|---|
| Founded | 2004 | 2004 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 350.9M | 317.7M |
| IPO Year | 2022 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ANL | ALDX |
|---|---|---|
| Price | $8.28 | $5.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $16.00 | $9.50 |
| AVG Volume (30 Days) | 459.6K | ★ 706.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 40.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $36.25 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.88 | $1.18 |
| 52 Week High | $12.09 | $7.19 |
Technical Indicators
Market Signals| Indicator | ANL | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 52.82 | 59.87 |
| Support Level | $1.36 | $4.74 |
| Resistance Level | $12.09 | $5.75 |
| Average True Range (ATR) | 0.82 | 0.29 |
| MACD | -0.47 | 0.02 |
| Stochastic Oscillator | 36.73 | 82.58 |
Price Performance
Historical ComparisonAbout ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.